{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:38:30Z","timestamp":1788273510745,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031531","name":"Travere Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xkme.2025.101218","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:13:44Z","timestamp":1765815224000},"page":"101218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management"],"prefix":"10.1016","volume":"8","author":[{"given":"Swetha R.","family":"Kanduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Amarapurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8247-5936","authenticated-orcid":false,"given":"Mohamed","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Q.","family":"Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib1","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1097-0142(19930215)71:4<1309::AID-CNCR2820710423>3.0.CO;2-M","article-title":"Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center","volume":"71","author":"Vassilopoulou-Sellin","year":"1993","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7861\/clinmedicine.17-3-270","article-title":"Hypercalcaemia\u2014presentation and management","volume":"17","author":"Turner","year":"2017","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"10.1016\/j.xkme.2025.101218_bib3","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.xkme.2025.101218_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12032-019-1315-8","article-title":"Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis","volume":"36","author":"Bhandari","year":"2019","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib6","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archsurg.1980.01380060012004","article-title":"Incidence of hypercalcemia and malignant neoplasm","volume":"115","author":"Burt","year":"1980","journal-title":"Arch Surg"},{"key":"10.1016\/j.xkme.2025.101218_bib7","series-title":"Hypercalcemia Associated with Malignant Disease. Endocrine and Nonendocrine Humoral Producing Tumors: Sixteenth Annual Clinical Conference on Cancer, M. D. Anderson Hospital and Tumor Institute","first-page":"147","author":"WPL","year":"1973"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3810\/pgm.2004.04.1486","article-title":"Understanding hypercalcemia. Its metabolic basis, signs, and symptoms","volume":"115","author":"Inzucchi","year":"2004","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib9","doi-asserted-by":"crossref","first-page":"F485","DOI":"10.1152\/ajprenal.00608.2009","article-title":"Physiology and pathophysiology of the calcium-sensing receptor in the kidney","volume":"298","author":"Riccardi","year":"2010","journal-title":"Am J Physiol Ren Physiol"},{"issue":"5","key":"10.1016\/j.xkme.2025.101218_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.kint.2016.12.005","article-title":"Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus","volume":"91","author":"Khositseth","year":"2017","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1172\/JCI110918","article-title":"Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium","volume":"71","author":"Levi","year":"1983","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/anec.12316","article-title":"Electrocardiographic manifestations of calcium abnormalities","volume":"21","author":"Chorin","year":"2016","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/j.ackd.2013.05.005","article-title":"Electrolyte disorders associated with cancer","volume":"21","author":"Rosner","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"15","key":"10.1016\/j.xkme.2025.101218_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMcp2113128","article-title":"Cancer-associated hypercalcemia","volume":"386","author":"Guise","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"10.1016\/j.xkme.2025.101218_bib16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199004193221603","article-title":"Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer","volume":"322","author":"Burtis","year":"1990","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.xkme.2025.101218_bib17","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: an update","volume":"97","author":"Wysolmerski","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.xkme.2025.101218_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ndt\/gfaa326","article-title":"Immune checkpoint inhibitor-associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.xkme.2025.101218_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae252","article-title":"Immobilization-associated hypercalcaemia in patients with malignancy in the hospital setting","volume":"17","author":"Kanduri","year":"2024","journal-title":"Clin Kidney J"},{"issue":"11","key":"10.1016\/j.xkme.2025.101218_bib20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4103\/1947-2714.170600","article-title":"Hypercalcemia of malignancy: an update on pathogenesis and management","volume":"7","author":"Mirrakhimov","year":"2015","journal-title":"N Am J Med Sci"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1677\/erc.1.00543","article-title":"Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone","volume":"12","author":"Clines","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/0008-5472.CAN-10-2993","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1681\/ASN.2007090981","article-title":"PTH-related peptide (PTHrP) in hypercalcemia","volume":"19","author":"Mundy","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.xkme.2025.101218_bib24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.xkme.2025.101218_bib25","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1210\/jc.2014-4250","article-title":"PTHrP-mediated hypercalcemia: causes and survival in 138 patients","volume":"100","author":"Donovan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib26","first-page":"510","article-title":"Physiological roles of parathyroid hormone-related protein","volume":"90","author":"Lai","year":"2019","journal-title":"Acta Biomed"},{"issue":"5275","key":"10.1016\/j.xkme.2025.101218_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1126\/science.273.5275.663","article-title":"PTH\/PTHrP receptor in early development and Indian hedgehog-regulated bone growth","volume":"273","author":"Lanske","year":"1996","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.xkme.2025.101218_bib28","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1172\/JCI26239","article-title":"Osteoblast-derived PTHrP is a physiological regulator of bone formation","volume":"115","author":"Martin","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/jcem-60-1-29","article-title":"Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia","volume":"60","author":"Rosenthal","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.xkme.2025.101218_bib30","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1210\/jc.2013-2016","article-title":"Calcitriol-mediated hypercalcemia: causes and course in 101 patients","volume":"98","author":"Donovan","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1210\/jc.2005-2095","article-title":"Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene","volume":"91","author":"VanHouten","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.xkme.2025.101218_bib32","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xkme.2025.101218_bib33","article-title":"Immobilization-induced hypercalcemia in a patient with renal failure","volume":"2021","author":"Gandhi","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"5","key":"10.1016\/j.xkme.2025.101218_bib34","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0272-6386(00)70272-1","article-title":"Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease","volume":"35","author":"Gopal","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2025.101218_bib35","article-title":"Hypercalcemia due to immobilization","volume":"5","author":"Ahamed","year":"2021","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.kint.2021.06.001","article-title":"Immune checkpoint inhibitor-associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System","volume":"100","author":"Wanchoo","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1159\/000502285","article-title":"Hypercalcaemia due to sarcoidosis during treatment with avelumab for metastatic Merkel cell carcinoma","volume":"12","author":"Tun Min","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.xkme.2025.101218_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100626","article-title":"Immune checkpoint inhibitor-associated sarcoidosis reaction in the kidney: case report","volume":"5","author":"Charkviani","year":"2023","journal-title":"Kidney Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2265.2002.01578.x","article-title":"Bone remodelling markers and serum cytokines in patients with hyperthyroidism","volume":"57","author":"Akalin","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4158\/EP.9.6.517","article-title":"Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis","volume":"9","author":"Iqbal","year":"2003","journal-title":"Endocr Pract"},{"key":"10.1016\/j.xkme.2025.101218_bib41","first-page":"223","article-title":"Adrenal insufficiency presenting as hypercalcemia and acute kidney injury","volume":"9","author":"Ahn","year":"2016","journal-title":"Int Med Case Rep J"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1158\/1078-0432.CCR-06-1487","article-title":"Parathyroid hormone-related protein induces cachectic syndromes without directly modulating the expression of hypothalamic feeding-regulating peptides","volume":"13","author":"Hashimoto","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xkme.2025.101218_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105942","article-title":"Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions","volume":"77","author":"Deligiorgi","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.xkme.2025.101218_bib45","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.xkme.2025.101218_bib46","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdw148","article-title":"Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases","volume":"27","author":"Kanai","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.xkme.2025.101218_bib47","article-title":"Letrozole induced hypercalcemia in a patient with breast cancer","volume":"2014","author":"Ipekci","year":"2014","journal-title":"Case Rep Oncol Med"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib48","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s12020-016-1006-6","article-title":"Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism","volume":"53","author":"Yu","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.xkme.2025.101218_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1039490","article-title":"Cancer-related hypercalcemia and potential treatments","volume":"14","author":"Almuradova","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"10.1016\/j.xkme.2025.101218_bib50","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.2215\/CJN.02470312","article-title":"Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia","volume":"7","author":"Rosner","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.xkme.2025.101218_bib51","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.xkme.2025.101218_bib52","first-page":"377","article-title":"Hypercalcemia and cancer: differential diagnosis and treatment","volume":"68","author":"Zagzag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.xkme.2025.101218_bib53","unstructured":"Singh S, Kerndt CC, Davis D. Ringer\u2019s lactate. In: StatPearls; 2024, StatPearls Publishing. Copyright \u00a9 2024, StatPearls Publishing LLC.: Treasure Island (FL) ineligible companies. Disclosure: Connor Kerndt declares no relevant financial relationships with ineligible companies. Disclosure: David Davis declares no relevant financial relationships with ineligible companies."},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-149-4-200808190-00007","article-title":"Narrative review: furosemide for hypercalcemia: an unproven yet common practice","volume":"149","author":"LeGrand","year":"2008","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-95-2-192","article-title":"Calcitonin as a drug","volume":"95","author":"Deftos","year":"1981","journal-title":"Ann Intern Med"},{"issue":"3-4","key":"10.1016\/j.xkme.2025.101218_bib56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10606820213681","article-title":"Molecular pharmacology of the calcitonin receptor","volume":"8","author":"Purdue","year":"2002","journal-title":"Recept Channels"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7326\/0003-4819-93-2-269","article-title":"Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy","volume":"93","author":"Binstock","year":"1980","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib58","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1210\/clinem\/dgac631","article-title":"A systematic review supporting the Endocrine Society clinical practice guideline on the treatment of hypercalcemia of malignancy in adults","volume":"108","author":"Seisa","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"12-suppl","key":"10.1016\/j.xkme.2025.101218_bib59","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.xkme.2025.101218_bib60","first-page":"539","article-title":"Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate","volume":"11","author":"Pecherstorfer","year":"2003","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib61","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib62","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90282-T","article-title":"Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages","volume":"95","author":"Nussbaum","year":"1993","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib63","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.xkme.2025.101218_bib65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2019446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib66","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0897190019883162","article-title":"Use of pamidronate for hypercalcemia of malignancy in renal dysfunction","volume":"34","author":"Norman","year":"2021","journal-title":"J Pharm Pract"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib67","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1060028020953501","article-title":"Safety of intravenous bisphosphonates for the treatment of hypercalcemia in patients with preexisting renal dysfunction","volume":"55","author":"Palmer","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.xkme.2025.101218_bib68","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jjco\/hyd105","article-title":"Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma","volume":"30","author":"Ohnishi","year":"2000","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib69","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.xkme.2025.101218_bib70","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib71","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib72","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155213518361","article-title":"Denosumab in hypercalcemia of malignancy: a case series","volume":"21","author":"Dietzek","year":"2015","journal-title":"J Oncol Pharm Pract"},{"issue":"16","key":"10.1016\/j.xkme.2025.101218_bib73","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to Zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.xkme.2025.101218_bib74","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.xkme.2025.101218_bib75","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1080\/10428194.2022.2115840","article-title":"Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma","volume":"63","author":"Lei","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib76","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jamaoncol.2022.7941","article-title":"Endocrine Society hypercalcemia of malignancy guidelines","volume":"9","author":"Dickens","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.xkme.2025.101218_bib77","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.xkme.2025.101218_bib78","article-title":"Incidence and risk factors of hypomagnesemia in patients with bone metastasis from solid malignancies treated with denosumab","author":"Donkor","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.xkme.2025.101218_bib79","article-title":"Severe hypocalcemia and hypomagnesemia with denosumab in advanced chronic kidney disease: case report and literature review","volume":"2018","author":"Marlow","year":"2018","journal-title":"Case Rep Oncol Med"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000499824","article-title":"Severe, symptomatic hypocalcemia due to denosumab administration: treatment and clinical course","volume":"9","author":"Strickling","year":"2019","journal-title":"Case Rep Nephrol Dial"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.xkme.2025.101218_bib82","article-title":"Severe hypocalcemia and dramatic increase in parathyroid hormone after denosumab in a dialysis patient: a case report and review of the literature","volume":"2019","author":"Bhanot","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.xkme.2025.101218_bib83","article-title":"Denosumab-induced severe hypocalcaemia in chronic kidney disease","volume":"2018","author":"Jalleh","year":"2018","journal-title":"Case Rep Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib84","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1210\/clinem\/dgz278","article-title":"Calcitriol elevation is associated with a higher risk of refractory hypercalcemia of malignancy in solid tumors","volume":"105","author":"Chukir","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1241821","article-title":"Hypercalcemia in cancer patients: pathobiology and management","volume":"42","author":"Santarpia","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.xkme.2025.101218_bib86","first-page":"1779","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0049-0172(05)80029-0","article-title":"Corticosteroid-induced osteoporosis","volume":"22","author":"Adachi","year":"1993","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib88","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1517\/17425255.2011.562196","article-title":"Clinical utilization of Cinacalcet in hypercalcemic conditions","volume":"7","author":"Messa","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib89","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-20-0487","article-title":"Treatment of malignancy-associated hypercalcemia with Cinacalcet: a paradigm shift","volume":"10","author":"O\u2019Callaghan","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.xkme.2025.101218_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110149","article-title":"Oral Cinacalcet responsiveness in non-parathyroid hormone mediated hypercalcemia of malignancy","volume":"143","author":"Sheehan","year":"2020","journal-title":"Med Hypotheses"},{"issue":"2","key":"10.1016\/j.xkme.2025.101218_bib91","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.xkme.2025.101218_bib92","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.394","article-title":"Immune-related adverse events from immune checkpoint inhibitors","volume":"100","author":"Marrone","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"9923","key":"10.1016\/j.xkme.2025.101218_bib93","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib94","first-page":"398","article-title":"Liver granulomatosis is not an exceptional cause of hypercalcemia with hypoparathyroidism in dialysis patients","volume":"12","author":"Hardy","year":"1999","journal-title":"J Nephrol"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib95","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3109\/00365599309182276","article-title":"Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure","volume":"27","author":"Davenport","year":"1993","journal-title":"Scand J Urol Nephrol"},{"issue":"10","key":"10.1016\/j.xkme.2025.101218_bib96","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/nep.13246","article-title":"Immobilization-induced severe hypercalcaemia successfully treated with reduced dose of zoledronate in a maintenance haemodialysis patient","volume":"23","author":"Yamada","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.xkme.2025.101218_bib97","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40001-022-00715-x","article-title":"Fine-tuned continuous renal replacement therapy with calcium-free dialysate to manage severe hypercalcemia refractory to medical and intermittent hemodialysis","volume":"27","author":"Scheen","year":"2022","journal-title":"Eur J Med Res"},{"issue":"4","key":"10.1016\/j.xkme.2025.101218_bib98","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MAT.0b013e31817dc3be","article-title":"Treatment of severe hypercalcemia using continuous renal replacement therapy with regional citrate anticoagulation","volume":"54","author":"Kindgen-Milles","year":"2008","journal-title":"ASAIO J"},{"issue":"6","key":"10.1016\/j.xkme.2025.101218_bib99","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.ajem.2018.03.011","article-title":"Management of hypercalcaemic crisis in adults: current role of renal replacement therapy","volume":"36","author":"Bentata","year":"2018","journal-title":"Am J Emerg Med"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:31:50Z","timestamp":1770366710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525002547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2590059525002547"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101218","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignancy-Associated Hypercalcemia and Kidney Disease: Facts, Controversies, and Management","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101218","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101218"}}